Physician profile
Dane Hill
NPI 1992118434
$12,593.22
in general payments reported to CMS, 2019-2025
31 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $661 · 2021: $2,496 · 2022: $1,919 · 2023: $2,705 · 2024: $1,997 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,536 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,535.97 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,033.31 | 2019-2025 | |
| Amgen INC. | $959.76 | 2020-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $917.09 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $873.64 | 2021-2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $840.98 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Janssen Biotech, INC. | $726.15 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $658.53 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $644.09 | 2019-2025 | |
| Pfizer INC. | $452.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $378.21 | 2022-2025 | |
| Incyte Corporation | $376.16 | 2021-2025 | Opzelura |
| Ucb, INC. | $311.58 | 2022-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $308.42 | 2020-2022 | |
| Misonix INC | $283.22 | 2021 | |
| Leo Pharma INC. | $269.56 | 2020-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $225.22 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $217.29 | 2023-2025 | Zoryve |
| Biowound Solutions, INC. | $150.41 | 2025 | Bio-Connekt |
| Bioventus LLC | $142.11 | 2022 | |
| Merz North America, INC. | $141.56 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $136.74 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.49 | 2020-2024 | Jublia |
| Mayne Pharma Commercial LLC | $86.80 | 2020-2025 | |
| Genentech USA, INC. | $86.18 | 2020 | |
| Epi Health, LLC | $75.58 | 2020-2021 | |
| Kyowa Kirin, INC. | $52.73 | 2020-2022 | |
| Allergan, INC. | $34.07 | 2021 | |
| Journey Medical Corporation | $24.87 | 2025 | |
| Strata Skin Sciences, INC. | $22.60 | 2023 | Xtrac |
| Botanix Sb INC | $20.30 | 2025 | Sofdra |
| Biofrontera INC. | $17.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.